Leukemia Research
Volume 33, Issue 11 , Pages 1454-1458 , November 2009

Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia

Received 9 December 2008 ,Revised 3 April 2009 ,Accepted 4 April 2009.

References 

  1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278(5340):1059–1064
  2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323–331
  3. Wu L, Levine AJ. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation p53-dependent and p53-independent regulation of the mdm2 gene. Mol Med. 1997;3(7):441–451
  4. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev. 2002;12(1):53–59
  5. Hu G, Zhang W, Deisseroth AB. P53 gene mutations in acute myelogenous leukaemia. Br J Haematol. 1992;81(4):489–494
  6. Nakano Y, Naoe T, Kiyoi H, Kitamura K, Minami S, Miyawaki S, et al. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. Eur J Haematol. 2000;65(1):23–31
  7. Soenen V, Preudhomme C, Roumier C, Daudignon A, Lai JL, Fenaux P. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood. 1998;91(3):1008–1015
  8. Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol. 2000;2(9):569–573
  9. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 1998;17(2):554–564
  10. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A. 1999;96(6):3077–3080
  11. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005;5(1):27–41
  12. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–365
  13. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19(2):1092–1100
  14. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis. 2003;18(4):377–385
  15. Weston A, Godbold JH. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect. 1997;105(Suppl. 4):919–926
  16. Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood. 2008;112(3):741–749
  17. Phang BH, Linn YC, Li H, Sabapathy K. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer. 2008;44(5):760–766
  18. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591–602
  19. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005;65(13):5481–5484
  20. Antoniou AC, Easton DF. Polygenic inheritance of breast cancer: implications for design of association studies. Genet Epidemiol. 2003;25(3):190–202
  21. Houlston RS, Peto J. The future of association studies of common cancers. Hum Genet. 2003;112(4):434–435
  22. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene. 2007;26(9):1317–1323
  23. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007;13(14):4123–4129
  24. Swinney RM, Hsu SC, Hirschman BA, Chen TT, Tomlinson GE. MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia. Leukemia. 2005;19(11):1996–1998
  25. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias French–American–British (FAB) co-operative group. Br J Haematol. 1976;33(4):451–458
  26. Lo Coco F, Foa R. Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia. Eur J Haematol. 1995;55(1):1–9
  27. Porwit-MacDonald A, Janossy G, Ivory K, Swirsky D, Peters R, Wheatley K, et al. Leukemia-associated changes identified by quantitative flow cytometry IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood. 1996;87(3):1162–1169
  28. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102(4):1232–1240
  29. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res. 1976;3(9):2303–2308
  30. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993;14(6):1085–1089
  31. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 2006;98(4):285–288
  32. Breslow NE, Day NE. Statistical methods in cancer research. Volume I—the analysis of case–control studies. IARC Sci Publ. 1980;32:5–338
  33. Brennan P. Gene–environment interaction and aetiology of cancer: what does it mean and how can we measure it?. Carcinogenesis. 2002;23(3):381–387
  34. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2717–2723
  35. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006;66(10):5104–5110
  36. Harris SL, Gil G, Robins H, Hu W, Hirshfield K, Bond E, et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci U S A. 2005;102(45):16297–16302
  37. Ishibe N, Wiencke JK, Zuo ZF, McMillan A, Spitz M, Kelsey KT. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. Cancer Epidemiol Biomarkers Prev. 1997;6(12):1075–1080
  38. Wrensch MR, Miike R, Sison JD, Kelsey KT, Liu M, McMillan A, et al. CYP1A1 variants and smoking-related lung cancer in San Francisco Bay area Latinos and African Americans. Int J Cancer. 2005;113(1):141–147
  39. Nakano Y, Naoe T, Kiyoi H, Kunishima S, Minami S, Miyawaki S, et al. Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. Leuk Res. 2000;24(4):349–352
  40. Sotamaa K, Liyanarachchi S, Mecklin JP, Jarvinen H, Aaltonen LA, Peltomaki P, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res. 2005;11(19 Pt 1):6840–6844
  41. Moorman AV, Roman E, Willett EV, Dovey GJ, Cartwright RA, Morgan GJ. Karyotype and age in acute myeloid leukemia. Are they linked?. Cancer Genet Cytogenet. 2001;126(2):155–161

PII: S0145-2126(09)00179-9

doi: 10.1016/j.leukres.2009.04.007

Leukemia Research
Volume 33, Issue 11 , Pages 1454-1458 , November 2009

Article Tools

* Image Usage & Resolution